Presentations


Xbrane Company Presentation May 2021

Press Releases

02 Jul 2021

Xbrane Biopharma certified as a Great Place to Work®

30 Jun 2021

Xbrane Biopharma has carried out a directed share issue raising gross proceeds of SEK 380 millions

30 Jun 2021

Xbrane Biopharma announces intention to carry out a directed share issue

30 Jun 2021

CHANGE OF NUMBER OF SHARES AND VOTES IN XBRANE

27 Jun 2021

Xlucane™ meets the primary endpoint in the pivotal Phase III trial with Xlucane™ – regulatory submission in EU and US planned for second half of 2021

16 May 2021

Xbrane announces ambition to generate positive operating cash flow monthly by late 2023/early 2024 and to initiate one new biosimilar development program per annum.

11 May 2021

Xbrane is hosting a Virtual Capital Markets Day on May 17th, 2021

06 May 2021

Announcement from Xbrane Biopharma’s annual general meeting

06 May 2021

Xbrane Biopharma releases interim report for January – March 2021

Financial Reports

18 Apr 2013

Annual report 2013 (available in Swedish only)

18 Apr 2014

Annual report 2014 (available in Swedish only)

31 Dec 2015

Annual report 2015 (available in Swedish only)

18 Dec 2015

Year-end report 2015 (available in Swedish only)

18 Apr 2015

Interim report January – September 2015 (available in Swedish only)

Financial Calendar

13 Aug 2021

Interim report January – June 2021

29 Oct 2021

Interim report January – September 2021

16 Feb 2022

Year-end report 2021

05 May 2022

Annual General Meeting

Contact Investor Relations

Anette Lindqvist, CFO & Head of Investor Relation

Presentations and media


PRESENTATION AT PARETO HELTHCARE CONFERENCE

September 3, 2020

Presentation at Vator Securities Unicorn Summit

November 27, 2019

Nasdaq Stockholm welcomes Xbrane

September 23, 2019

Presentation at LSX Nordic Congress

August 29, 2019

Presentation at BioStock Live

March 20, 2019